MiMedx(US:MDXG) Globenewswire·2025-10-29 20:01Core Insights - MiMedx Group, Inc. reported its highest quarterly net sales in history for Q3 2025, reaching $114 million, a 35% increase year-over-year [1][3] - The company achieved a GAAP net income of $17 million and diluted earnings per share of $0.11 for the same quarter [1][7] - Adjusted EBITDA for Q3 2025 was $35 million, representing 31% of net sales, with expectations for continued growth in net sales and adjusted EBITDA for 2025 [1][9] Financial Performance - Net Sales: Q3 2025 net sales were $114 million, up from $84 million in Q3 2024, driven by a 40% increase in Wound product sales and a 26% increase in Surgical product sales [3][31] - Gross Profit and Margin: Gross profit for Q3 2025 was $95 million, with a gross margin of 84%, an increase from 82% in the prior year [4] - Operating Expenses: SG&A expenses rose to $69 million from $54 million year-over-year, primarily due to increased commissions [5] - Net Income: Net income for Q3 2025 was $17 million, compared to $8 million in Q3 2024 [7] Cash Position - As of September 30, 2025, the company had $142 million in cash and cash equivalents, up from $104 million at the end of 2024 [8] Financial Outlook - MiMedx expects net sales growth in the mid-to-high teens for 2025, with an adjusted EBITDA margin projected to be at least in the mid-20% range [9] Product Performance - Wound Products: Sales for Wound products reached $77.1 million in Q3 2025, a significant increase from $55.1 million in Q3 2024 [31] - Surgical Products: Surgical product sales were $36.6 million in Q3 2025, compared to $29.0 million in the same quarter of the previous year [31]